Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy
Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy
复制标题
DOI：
10.1158/0008-5472.can-04-4106
复制
发表时间：
2005-04-15
期刊：
影响因子：
11.2
通讯作者：
Wu, CL
中科院分区：
文献类型：
--
作者：
Cheng, LL;Burns, MA;Wu, CL
前列腺癌的诊断进步已大大增加了早期发现，希望改善患者预后。然而，指导治疗的组织病理学通常将侵略性不足地分为中等分化的格里森评分（6和7）肿瘤（> 70％的新病例）。在这里，我们测试了使用完整的组织磁共振光谱测量的前列腺代谢物谱的诊断能力，以及局部前列腺代谢物在预测前列腺癌状况方面的敏感性。前列腺组织样品（n = 199）用高分辨率的魔术角旋转质子磁共振光谱分析前列腺癌切除术后82例前列腺癌患者，然后使用定量病理学分析。通过使用线性回归分析分析，从磁共振光谱的主成分分析获得的代谢物谱分析与病理定量发现相关，并使用ANOVA对患者病理状态进行了评估。配对t检验表明，组织代谢物谱可以将恶性与从同一患者获得的良性样本区分开（p <0.005），并与患者血清前列腺特异性抗原水平（P <0.006）相关。此外，从组织学良性的组织样品6和7前列腺中获得的代谢物谱样品可以描绘出侵袭性较低的肿瘤的子集（P <0.008），并预测子群中肿瘤周期侵袭（P <0.03）。这些结果表明，活检组织的磁共振光谱代谢物特征可能通过评估前列腺癌症病理阶段和侵略性来帮助指导治疗计划，目前只能在前列腺切除术后在组织病理学上确定。
Diagnostic advancements for prostate cancer have so greatly increased early detections that hope abounds for improved patient outcomes. However, histopathology, which guides treatment, often subcategorizes aggressiveness insufficiently among moderately differentiated Gleason score (6 and 7) tumors (> 70% of new cases). Here, we test the diagnostic capability of prostate metabolite profiles measured with intact tissue magnetic resonance spectroscopy and the sensitivity of local prostate metabolites in predicting prostate cancer status. Prostate tissue samples (n = 199) obtained from 82 prostate cancer patients after prostatectomy were analyzed with high-resolution magic angle spinning proton magnetic resonance spectroscopy, and afterwards with quantitative pathology. Metabolite profiles obtained from principal component analysis of magnetic resonance spectroscopy were correlated with pathologic quantitative findings by using linear regression analysis and evaluated against patient pathologic statuses by using ANOVA. Paired t tests show that tissue metabolite profiles can differentiate malignant from benign samples obtained from the same patient (P < 0.005) and correlate with patient serum prostate-specific antigen levels (P < 0.006). Furthermore, metabolite profiles obtained from histologically benign tissue samples of Gleason score 6 and 7 prostates can delineate a subset of less aggressive tumors (P < 0.008) and predict tumor perineural invasion within the subset (P < 0.03). These results indicate that magnetic resonance spectroscopy metabolite profiles of biopsy tissues may help direct treatment plans by assessing prostate cancer pathologic stage and aggressiveness, which at present can be histopathologically determined only after prostatectomy.